Filing Analysis
IN8bio, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2026.
- Filing date: August 6, 2026.
- The filing includes a press release (Exhibit 99.1) containing the financial results.
IN8bio, Inc. has entered into a new 'Capital on Demand' At-The-Market (ATM) sales agreement with JonesTrading Institutional Services LLC to sell common stock. Simultaneously, the company terminated its previous controlled equity offering agreement with Cantor Fitzgerald & Co.
🚩 Red Flags
- Potential for significant shareholder dilution as the company establishes a mechanism to sell shares into the open market at its discretion.
📋 Key Facts
- Entered into a new ATM Sales Agreement with JonesTrading Institutional Services LLC on June 1, 2026.
- The company will pay JonesTrading a commission of 3.0% of the gross sales proceeds.
- The offering is conducted under an existing Form S-3 registration statement (File No. 333-291393).
- Mutually terminated the previous Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. effective May 29, 2026.
- No termination penalties were incurred for ending the Cantor Fitzgerald agreement.
IN8bio, Inc. reported its Q1 2026 financial results and announced the results of its 2026 Annual Meeting of Stockholders. Shareholders approved an Amended and Restated 2026 Equity Incentive Plan, which increases the share pool and extends the plan's duration.
🚩 Red Flags
- Potential shareholder dilution resulting from the 2,920,000 share increase in the equity incentive plan and the extension of the evergreen provision through 2037.
📋 Key Facts
- Announced Q1 2026 financial results for the period ended March 31, 2026.
- Stockholders approved the Amended and Restated 2026 Equity Incentive Plan, increasing the share pool by 2,920,000 shares.
- The 2026 Plan extends the annual share increase ('evergreen') provision through 2037.
- Established a maximum of 20,000,000 shares for issuance as Incentive Stock Options (ISOs).
- Peter Brandt and Corinne Epperly were elected as Class II directors to serve until 2029.
- CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
IN8bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release on March 12, 2026.
📋 Key Facts
- The filing reports financial results for the fiscal year ended December 31, 2025.
- The information was furnished under Item 2.02 Results of Operations and Financial Condition.
- The report was signed by Patrick McCall, Chief Financial Officer and Secretary.
- A press release dated March 12, 2026, was included as Exhibit 99.1.
Alan S. Roemer resigned from the Board of Directors and its Audit and Compensation Committees effective February 28, 2026. The company has appointed independent director Jeremy Graff as Interim Chair of the Board to fill the vacancy.
🚩 Red Flags
- Resignation from the Audit Committee, which requires oversight of financial reporting.
- Appointment of an 'Interim' Chair suggests an unplanned transition or lack of a permanent succession plan.
📋 Key Facts
- Alan S. Roemer notified the Board of his resignation on February 26, 2026.
- The resignation is effective as of February 28, 2026.
- Mr. Roemer was a member of both the Audit and Compensation Committees.
- Jeremy Graff, an independent director, was appointed as Interim Chair of the Board.
- The filing states the resignation was not the result of any disagreement with the Company.
IN8bio, Inc. announced that the Board of Directors has appointed current Chief Operating Officer Kate Rochlin to the role of President, effective February 4, 2026.
📋 Key Facts
- Effective Date: February 4, 2026
- Appointee: Dr. Kate Rochlin
- New Role: President of the Company
- Existing Role: Chief Operating Officer (retained)
- No family relationships or related-party transactions reported regarding this appointment.
IN8bio, Inc. entered into a Securities Purchase Agreement for a two-tranche private placement of common stock and pre-funded warrants totaling up to approximately $40.2 million. The second tranche is contingent upon achieving specific clinical/animal model milestones and maintaining a significant stock price threshold.
🚩 Red Flags
- Significant potential dilution: The second tranche could issue over 14.5 million additional shares/warrants if milestones are met.
- Contingent financing structure: The company's ability to access the full $40.2M is tied heavily to clinical data success and stock price performance, creating high uncertainty in cash runway projections.
- Pre-funded warrants with near-zero exercise prices ($0.0001) act as immediate equity upon exercise, leading to rapid dilution.
📋 Key Facts
- Initial Closing (expected Dec 22, 2025): Up to 5,127,029 shares of Common Stock and up to 9,452,677 Pre-Funded Warrants for ~$20.1 million.
- Second Closing Trigger: Achievement of INB-619 animal model data milestone by Dec 31, 2026 AND a VWAP price threshold of 200% of the initial share price ($2.76) over five consecutive trading days.
- Second Closing Amount: Up to an additional 14,579,706 shares/warrants for ~$20.1 million.
- Pre-Funded Warrants have an exercise price of $0.0001 per share and are immediately exercisable.
- Registration Rights Agreement requires the company to file a registration statement within 30 days of closing, with liquidated damages of 1% per 30-day period for delays.
IN8bio, Inc. presented clinical data from its Phase 1 trial of INB-200 and Phase 2 trial of INB-400 at the 2025 Society for Neuro-Oncology Annual Meeting. The data focuses on treatment efficacy for patients with newly diagnosed glioblastoma (GBM) using DeltEx DRI gamma-delta T cells.
📋 Key Facts
- Presented clinical trial data at the 2025 SNO Annual Meeting on Nov 21-22, 2025.
- Phase 1/2 trials involved 17 patients treated with DeltEx DRI gamma-delta T cells; 14 received repeated doses (3 to 6 doses).
- Patients receiving repeated DeltEx DRI doses achieved a median progression-free survival (mPFS) of 13.0 months.
- Standard-of-care (SOC) control group (n=10) achieved an mPFS of 6.6 months.
- Median overall survival (mOS) for DeltEx DRI repeated dose group has not yet been reached, currently climbing at 16.4+ months as of Oct 31, 2025.
- SOC control group attained a mOS of 11.0 months.
IN8bio, Inc. filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Reporting date: November 6, 2025
- Period covered: Third quarter ended September 30, 2025
- The filing includes Exhibit 99.1, which contains the official press release regarding financial results.
- Company is classified as an 'Emerging Growth Company'.
IN8bio, Inc. announced the presentation of new preclinical data for its gd-T cell engager (gd-TCE) program, INB-619, at the 2025 American College of Rheumatology (ACR) Convergence Meeting.
📋 Key Facts
- Presentation occurred on October 27, 2025, at the ACR Convergence Meeting in Chicago.
- The data pertains to the preclinical stage of the INB-619 program.
- Program focus is gd-T cell engager (gd-TCE) technology.
IN8bio, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2025. The filing serves as a formal mechanism to furnish the quarterly press release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Filing date: August 7, 2025.
- The filing includes a press release (Exhibit 99.1) containing the company's financial results.
- Company is classified as an 'emerging growth company'.
IN8bio, Inc. has officially regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The company reports that the delisting matter regarding this specific rule is now closed.
🚩 Red Flags
- Historical delisting risk (the company was previously non-compliant with the minimum bid price requirement).
📋 Key Facts
- Received formal notification from Nasdaq on June 24, 2025, confirming compliance with Listing Rule 5550(a)(2).
- The requirement was to maintain a minimum bid price of at least $1.00 per share.
- Nasdaq has declared the matter regarding this specific rule as closed.
IN8bio, Inc. has filed a Certificate of Amendment to implement a 1-for-30 reverse stock split effective June 5, 2025. This action aims to consolidate outstanding shares from approximately 103.3 million down to roughly 3.4 million.
🚩 Red Flags
- Reverse stock split (often used to prevent delisting or manage share price)
- Significant reduction in total outstanding shares (96.6% reduction)
📋 Key Facts
- Reverse stock split ratio is 1-for-30.
- Effective date: June 5, 2025, at 5:00 p.m. ET.
- New trading begins on Nasdaq Capital Market on a split-adjusted basis on June 6, 2025.
- Shares outstanding prior to split (as of June 2, 2025): 103,327,028.
- Estimated shares outstanding post-split: ~3,444,234.
- New CUSIP number: 45674E208.
- Fractional shares will be paid out in cash.
IN8bio, Inc. issued a press release regarding positive Phase 1 data for its drug candidate INB-200 in patients with newly diagnosed glioblastoma multiforme. The data was presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
📋 Key Facts
- Announced Phase 1 data for INB-200 on June 2, 2025.
- The study focused on patients with newly diagnosed glioblastoma multiforme.
- Data demonstrated prolonged progression-free survival (PFS).
- Clinical data was presented via oral presentation at the 2025 ASCO Annual Meeting.
IN8bio, Inc. held its annual meeting of stockholders on May 8, 2025, where shareholders approved a series of amendments to the Certificate of Incorporation to effect a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to maintain Nasdaq listing compliance following significant share price depreciation.
📋 Key Facts
- Annual Meeting held on May 8, 2025.
- Three directors (Emily Fairbairn, Jeremy Graff, and Luba Greenwood) were elected to serve until the 2028 annual meeting.
- Stockholders ratified the appointment of CohnReznick LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- The 'Reverse Stock Split Proposal' was approved by shareholders with 43,559,092 votes in favor.
IN8bio, Inc. filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 7, 2025
- Reporting period: First Quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
IN8bio, Inc. issued an 8-K to announce the presentation of new preclinical data from its gdT cell engager (gd-TCE) platform at the 2025 AACR Annual Meeting.
📋 Key Facts
- Company presented preclinical data for its gd-TCE platform.
- Presentation occurred at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
- The filing was made on April 28, 2025.
IN8bio, Inc. entered into a series of complex transactions involving warrant exercises, exchanges, and amendments to existing securities purchase agreements to raise approximately $1.9 million in gross proceeds. The deal involves significant dilution through the issuance of new shares via pre-funded warrants at a nominal exercise price of $0.0001.
🚩 Red Flags
- Extreme dilution risk: Issuance of pre-funded warrants with a $0.0001 exercise price significantly dilutes existing shareholders.
- Severe downward adjustment of warrant exercise prices (from $1.50 to $0.45) indicates significant distress or loss of value in previous instruments.
- Highly compressed timeline: Transactions must be finalized by May 2, 2025.
- Complex restructuring involving insiders/directors at preferential pricing ($0.1844 vs $0.1784).
📋 Key Facts
- Company expects aggregate gross proceeds of approximately $1.9 million from the transactions.
- Series A and B Warrants will be exercised at reduced prices: $0.1844 for directors/officers and $0.1784 for other participating holders.
- Warrant Exchanges involve Bios Clinical Opportunity Fund, LP and William Ho surrendering warrants for pre-funded warrants to purchase 1,230,449 shares at an exercise price of $0.0001 per share.
- Series B Warrant exercise price is being reduced from $1.50 to $0.45 per share for non-exercised portions.
- Transactions must be completed by the 'Termination Date' of May 2, 2025.
IN8bio, Inc. has filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024.
- Filing date: March 13, 2025.
- The report includes Exhibit 99.1 containing the earnings press release.
IN8bio, Inc. announced the resignation of Travis Whitfill from the Board of Directors and its committees, effective May 9, 2025. The company stated that the resignation is not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Travis Whitfill resigned from the Board of Directors and all committees on March 4, 2025.
- The resignation becomes effective as of May 9, 2025.
- The company explicitly stated there were no disagreements with the Company regarding operations, policies, or practices.
IN8bio, Inc. issued an 8-K to announce the launch of its new gamma delta T cell engager platform targeting oncology and autoimmune diseases.
📋 Key Facts
- Company announced a new gamma delta T cell engager platform on March 3, 2025.
- The platform is designed for applications in both oncology and autoimmune diseases.
- Filing includes a press release as Exhibit 99.1.
IN8bio, Inc. announced the presentation of updated data from its ongoing Phase 1 investigator-sponsored trial of INB-100 at the ASTCT/CIBMTR Tandem Meetings on February 11, 2025.
📋 Key Facts
- Company presented updated data for INB-100, an allogeneic gamma-delta T cell therapy.
- The trial is a Phase 1 investigator-sponsored study targeting complex leukemias.
- Presentation occurred at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
IN8bio, Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement ($1.00). The company's stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective February 7, 2025.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement.
- Explicit mention of a potential reverse stock split to regain compliance.
- Downgrade in market tier (Nasdaq Global Market to Nasdaq Capital Market).
📋 Key Facts
- Nasdaq granted an extension until August 4, 2025, to regain compliance with the minimum closing bid price requirement (Rule 5550(a)(2)).
- Compliance requires a minimum bid price of $1.00 per share for at least 10 consecutive business days.
- The company's listing was transferred from Nasdaq Global Market to Nasdaq Capital Market on February 7, 2025.
- The 2025 Annual Meeting of Stockholders is scheduled for May 8, 2025, with a record date of March 12, 2025.
- Stockholder proposals or director nominations must be received by the company no later than February 17, 2025.
IN8bio, Inc. issued an 8-K to announce the presentation of updated clinical data from its Phase 1 investigator-sponsored trial of INB-100 at the 2024 American Society of Hematology Annual Meeting.
📋 Key Facts
- Announced updated data for INB-100 (allogeneic gamma-delta T cells) for leukemias.
- Data presented at the 2024 American Society of Hematology (ASH) Annual Meeting.
- Trial is a Phase 1 investigator-sponsored trial demonstrating continued progression-free survival.
IN8bio, Inc. issued an 8-K to announce new clinical data from its investigator-sponsored Phase 1 trial of INB-200 for the treatment of glioblastoma.
📋 Key Facts
- Announcement date: November 25, 2024
- Subject matter: Investigator-sponsored Phase 1 trial data for INB-200
- Indication: Glioblastoma
- The filing incorporates a press release as Exhibit 99.1
IN8bio, Inc. filed an 8-K to furnish its third quarter financial results for the period ended September 30, 2024. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Company is classified as an emerging growth company.
IN8bio, Inc. entered into a Securities Purchase Agreement on September 30, 2024, to raise approximately $12.4 million through the issuance of units containing common stock and significant warrant coverage. The financing includes pre-funded warrants and Series C warrants, alongside an amendment to existing Series A warrants that significantly reduces their exercise price.
🚩 Red Flags
- Significant dilution: The issuance of over 31 million Series C warrants and 5.6 million pre-funded warrants represents massive potential dilution for existing shareholders.
- Deeply discounted warrant pricing: Series A exercise price slashed from $1.25 to $0.45, and new Series C warrants at $0.27, both well below previous valuations/prices.
- Death spiral characteristics: The combination of low-priced warrants and the requirement for the company to pay liquidated damages (1% per 30 days) if registration is delayed acts as a penalty that incentivizes rapid dilution.
- Heavy warrant coverage: Total number of potential shares via warrants significantly exceeds the amount of common stock being sold in the primary offering.
📋 Key Facts
- Aggregate gross proceeds: approximately $12.4 million (before fees).
- Issuance of 25,759,595 shares of common stock and various warrants.
- Pre-Funded Warrants: 5,646,853 units with an exercise price of $0.0001 per share.
- Series C Warrants: 31,406,448 warrants with an exercise price of $0.27 per share.
- Unit purchase price: $0.3950 (or $0.3949 for pre-funded units).
- The company expects these funds to support operations into 2026.
- Series A Warrants amendment: Exercise price reduced from $1.25 to $0.45 per share.
IN8bio, Inc. announced that Chief Medical Officer Dr. Trishna Goswami has stepped down from her position effective September 6, 2024. The departure was described as a mutual decision and includes a severance package.
🚩 Red Flags
- Sudden departure of a C-suite officer (CMO) can sometimes signal internal friction, though the 'mutual decision' phrasing is standard for amicable exits.
📋 Key Facts
- Dr. Trishna Goswami stepped down as Chief Medical Officer on September 6, 2024.
- The departure is characterized as a 'mutual decision'.
- Severance benefit consists of two months of her annual base salary in cash.
- The separation agreement includes a general release of claims and customary non-disparagement/confidentiality covenants.
IN8bio, Inc. has amended the employment agreements for five key executives as part of a previously announced strategic plan and workforce reduction. These amendments involve significant reductions in cash compensation effective September 1, 2024.
🚩 Red Flags
- Significant reduction in executive cash compensation typically indicates severe liquidity constraints.
- Execution of a 'workforce reduction' and 'revised strategic plan' suggests the company is in cost-cutting mode to preserve runway.
📋 Key Facts
- Amendments made to employment agreements for William Ho, Trishna Goswami, Lawrence Lamb, Patrick McCall, and Kate Rochlin.
- Effective date of compensation reduction: September 1, 2024.
- The changes are part of a 'previously announced revised strategic plan and related workforce reduction'.
- Amendments include severance provisions triggered by termination without cause, resignation for good reason, or change of control.
IN8bio, Inc. announced a significant workforce reduction of approximately 49%, cutting staff from 37 to 19 employees, alongside a 11% pay cut for executives and management. The company is also exploring 'strategic alternatives' while prioritizing its pipeline to reduce costs.
🚩 Red Flags
- Significant workforce reduction (nearly 50% of staff) suggests severe liquidity or operational distress.
- Explicit mention of 'exploring other strategic alternatives' is often a precursor to sale, merger, or bankruptcy proceedings.
- Potential for future impairment charges related to pipeline prioritization.
- Management pay cuts indicate an urgent need to preserve cash.
📋 Key Facts
- Workforce reduction: Staff decreased from 37 to 19 full-time employees as of September 4, 2024.
- Executive compensation: Management and Board agreed to an 11% cash compensation reduction effective September 1, 2024.
- One-time costs: Estimated at approximately $0.3 million, primarily related to severance payments.
- Strategic shift: The company is prioritizing its pipeline and exploring 'other strategic alternatives.'
- Severance terms: Affected employees receive severance, health insurance continuation, and accelerated vesting/extension of equity awards until September 4, 2027.
IN8bio, Inc. issued a press release announcing updated positive clinical data from its Phase 1 investigator-sponsored trials for INB-100 (AML) and INB-200 (glioblastoma). The filing serves as a vehicle to incorporate the clinical update into the company's official SEC record.
📋 Key Facts
- Announced updated positive clinical data from Phase 1 investigator-sponsored trials.
- Data pertains to two candidates: INB-100 for Acute Myeloid Leukemia (AML) and INB-200 for glioblastoma.
- The announcement was made via press release on August 12, 2024.
IN8bio, Inc. received a deficiency notice from Nasdaq because its common stock bid price closed below $1.00 for 31 consecutive business days. The company has until February 3, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice (Nasdaq Rule 5450(a)(1))
- Potential for mandatory reverse stock split to regain compliance
- Prolonged period of sub-$1.00 trading indicating weak market sentiment or liquidity issues
📋 Key Facts
- Received Nasdaq notification on August 6, 2024, regarding a minimum bid price deficiency.
- The stock closed below $1.00 for the last 31 consecutive business days.
- Compliance deadline is February 3, 2025 (180-day period).
- To regain compliance, the closing bid must be at least $1.00 for ten consecutive business days before the deadline.
- The company may need to effect a reverse stock split to meet requirements if it seeks a second 180-day extension via transfer to Nasdaq Capital Market.
IN8bio, Inc. reported the results of its annual meeting of stockholders held on June 12, 2024. The filing confirms the election of two directors and the ratification of CohnReznick LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 12, 2024.
- William Ho was elected to the Board of Directors (25,153,626 votes for).
- Alan S. Roemer was elected to the Board of Directors (25,151,543 votes for).
- Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Company released updated Phase 1 trial data for INB-100 at the European Hematology Association 2024 Hybrid Congress.
IN8bio, Inc. issued an 8-K to announce the release of preliminary clinical data from its Phase 1 study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
📋 Key Facts
- Announced preliminary clinical data for the Phase 1 study of INB-200.
- Data was presented via a poster presentation at the 2024 ASCO Annual Meeting.
- The announcement occurred on June 3, 2024.
IN8bio, Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: First quarter ended March 31, 2024
- The filing is a standard announcement of quarterly financial results via press release (Exhibit 99.1).
- Company is an emerging growth company.
IN8bio, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 14, 2024
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Company is an emerging growth company.